For gastric cancers located in the corpus and antrum, radiotherapy can be used based on the MDTB decision.
However, a MDTB should monitor this treatment until more reliable data on this subject are available (Statement 21).
Statement 21: The decision on curative surgery for oligometastatic gastric cancer following systemic chemotherapy should be made by the MDTB. In patients with isolated peritoneal metastasis, CRS with HIPEC can be performed if the peritoneal carcinomatosis index is low and if disease is under control with systemic chemotherapy.
Statement 22: If there is a contraindication for surgery, non-operative management can be suggested in patients with pathologically proven complete response after neoadjuvant treatment based on the MDTB decision by discussing with patients all current data indicating that this is not a standard treatment for gastric cancer.